**Effect of aerosol propellants and surfactants on airway resistance**

G. M. STERLING and J. C. BATTEN

From St. George's Hospital, London, S.W.1

The effects on the airways of inhalation of the vehicles used in two commercial pressurized bronchodilator aerosols were studied in 20 normal and seven asthmatic subjects. Changes in bronchial calibre due to bronchoconstriction were measured as changes in airway resistance using a constant volume whole body plethysmograph, and results were expressed as changes in the ratio Airway conductance/Thoracic gas volume (=specific airway conductance). The aerosols caused very slight bronchoconstriction in the normal subjects, with a mean decrease of 5.3% in specific airway conductance after inhalation of a spray containing sorbitol trioleate as a surface tension lowering agent, and of 9.7% after inhalation of a spray containing lecithin. This effect was prevented by prior inhalation of atropine methonitrate, and its mechanism was therefore probably a vagally mediated reflex. The bronchoconstriction was also reversed by the addition of isoprenaline to the aerosol. The asthmatic subjects showed larger mean reductions in specific airway conductance of 13% and 21% after sorbitol and lecithin respectively; the response was again prevented by atropine. We conclude that, although the aerosol vehicles cause slight bronchoconstriction, this is unlikely to be a clinical danger since it is insufficient to cause symptoms of wheezing, and is less than that caused by inhalation of a single cigarette. Moreover, the constriction is regularly converted to dilatation in both normal and asthmatic subjects by the addition of atropine or isoprenaline to the aerosol.

There have recently been several reports of asthmatic deaths associated with the use of pressurized catecholamine aerosols (Keighley, 1966; Pickvance, 1967; Greenberg and Pines, 1967), and there is statistical evidence that there has been an increase in the death rate from asthma, particularly among young patients, since the introduction of these aerosols (Speizer, Doll, and Heaf, 1968a; Speizer, Doll, Heaf, and Strang, 1968b). The cause of the asthmatic deaths is unknown, but if it is connected with the use of aerosols it could be due either to overdosage with catecholamines or to toxicity or bronchoconstriction from the vehicles used in the sprays (Plaut, 1967; Freedman, 1967; Valtonen, 1967). The present study was undertaken to investigate the effect of these vehicles on bronchoconstriction in normal and asthmatic subjects.

**MATERIAL AND METHODS**

**AEROSOLS** The active agent in a pressurized aerosol is carried in an inert propellant, to which is added a surface-tension lowering agent to maintain fairly even, small droplet size. The propellants are usually halogenated hydrocarbons which are normally gaseous but easily liquefied, at room temperature. They have been investigated previously and found to be non-toxic (Kubler, 1964), though broncho-constrictor activity does not seem to have been excluded. In the present study the main propellant used was dichlor-difluoroethane throughout, but the surfactant was varied for comparison. The two investigated were sorbitol trioleate, which is used in an isopenaline spray (Medihaler Iso; Riker) and soya lecithin, which is used in an orciprenaline spray (Alupent; Boehringer Ingelheim).

**AIRWAY RESISTANCE** Airway resistance (Raw) was measured using a constant volume whole body plethysmograph as described in detail previously (DuBois, Botelho, Bedell, Marshall, and Comroe, 1956; DuBois, Botelho, and Comroe, 1956). The subjects sat in the plethysmograph, and after warming up for two or three minutes performed short bursts of shallow panting respiration through a heated flowmeter (Fleisch pneumotachograph) which could be closed by a remotely controlled shutter while gentle respiratory efforts were continued. The resulting flow/plethysmograph pressure and mouth pressure/
plethysmograph pressure signals were displayed as narrow, almost linear, vector loops on an oscilloscope. Their slopes were measured by visual alignment with a ruled Perspex disc which rotated within a fixed protractor scale in front of the oscilloscope screen. Each value of airway resistance was calculated from the mean of five successive short bursts of panting, and after subtraction of 0·45 cm. H₂O/1·sec. for the resistance of the pneumotachograph, Raw was converted to its reciprocal, airway conductance (Gaw). Thoracic gas volume (Vtg) was measured during the performance of respiratory efforts against the closed shutter, and was used to correct conductance, which has been found to increase almost linearly with increasing lung volume (Briscoe and DuBois, 1958; Butler, Caro, Alcala, and Dubois, 1960; Guyatt, Alpers, Hill, and Bramley, 1967). Results were finally expressed as changes in the ratio Gaw/Vtg, which is specific conductance (SGaw).

PROCEDURE

During each test, the subject practised shallow panting until he could produce consistent vector slopes, and a control value of SGaw was then measured. A second value was obtained shortly (within 90 seconds) after the inhalation of 10 deep breaths of an aerosol consisting of dichlorodifluoroethane, with either sorbitol trioleate or soya lecithin as a surfactant. After a rest of 15 minutes the whole procedure was repeated with the other surfactant in the same propellant. The test was semi-blind in that the operator who was reading the angles of the vector loops did not know the order in which the aerosols were inhaled until he was told by the subject at the end. If a change in SGaw lasted for more than 15 minutes, the rest period between inhalations was prolonged until SGaw had returned to its control value ±10%, so that all tests started from a similar resting state.

SUBJECTS

Twenty normal adults were studied before and after inhalation of aerosols containing sorbitol trioleate and lecithin as surfactant. A smaller group of 13 was selected on grounds of availability and consistency of results, and the response of these to the aerosols was studied again after the inhalation of five breaths of another aerosol containing atropine methonitrate 0·04 mg. per puff. Nine normal subjects were also studied after the inhalation of three breaths of a standard isoprenaline spray (Medihaler Iso ; Riker).

Seven asthmatic subjects were studied before and after inhalation of the sorbitol trioleate and lecithin aerosols, and the tests were repeated on five of them after inhalation of atropine.

It was ensured that none of the subjects had smoked for 90 minutes before starting a test in view of the bronchoconstrictor action of cigarette smoke (Nadel and Comroe, 1961 ; Zamel, Youssef, and Prime, 1963 ; Sterling, 1967).

RESULTS

Tables I and II show the effect of inhalation of aerosols containing only dichlorodifluoroethane and either lecithin or sorbitol trioleate. There was a slight fall in mean airway conductance with both surfactants; a slightly larger response occurred after lecithin, but this was not significantly different from that seen after sorbitol trioleate (t=1·6,
P>0·1). The changes were present within one minute of the inhalation and usually wore off within five minutes, suggesting that they were caused by bronchial muscle contraction rather than by bronchial oedema or excess mucus secretion. The mechanism of this bronchoconstriction was investigated by repeating the test after inhalation of not more than 0·2 mg. of atropine methonitrate. This caused bronchodilatation and prevented any constrictor response to subsequent inhalations of the dummy aerosols (Table II). The effect of an isoprenaline aerosol containing sorbitol is also shown in Table II; there was a consistent rise in SGaw, indicating bronchodilatation.

TABLE I

<table>
<thead>
<tr>
<th>Aerosol</th>
<th>Subjects</th>
<th>Mean SGaw±S.D.</th>
<th>% Change</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>After</td>
<td>Before</td>
<td>After</td>
<td>% Change</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>Lecithin</td>
<td>20</td>
<td>0·220±0·056</td>
<td>0·206±0·049</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>Lecithin</td>
<td>20</td>
<td>0·214±0·058</td>
<td>0·192±0·048</td>
</tr>
</tbody>
</table>

TABLE II

<table>
<thead>
<tr>
<th>Aerosol</th>
<th>Subjects</th>
<th>Mean % Change in SGaw</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>Atropine</td>
<td>13</td>
<td>−8·62</td>
</tr>
<tr>
<td>Lecithin</td>
<td>13</td>
<td>−11·68</td>
<td>t=3·38 P &lt; 0·01</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>13</td>
<td>+40·09</td>
<td>t=11·73 P &lt; 0·001</td>
</tr>
<tr>
<td>After</td>
<td>Atropine</td>
<td>13</td>
<td>−0·11</td>
</tr>
<tr>
<td>Lecithin</td>
<td>13</td>
<td>+0·48</td>
<td>t=0·46 P &gt; 0·70</td>
</tr>
<tr>
<td>Isoprenaline</td>
<td>13</td>
<td>+34·2</td>
<td>t=9·89 P &lt; 0·001</td>
</tr>
</tbody>
</table>

TABLE III

<table>
<thead>
<tr>
<th>Aerosol</th>
<th>Subjects</th>
<th>Mean % Change in SGaw</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>Atropine</td>
<td>7</td>
<td>−13·49</td>
</tr>
<tr>
<td>Lecithin</td>
<td>7</td>
<td>−21·33</td>
<td>t=3·35 P &lt; 0·02</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>5</td>
<td>+64·70</td>
<td>t=4·31 P &lt; 0·02</td>
</tr>
<tr>
<td>After</td>
<td>Atropine</td>
<td>5</td>
<td>+1·16</td>
</tr>
<tr>
<td>Lecithin</td>
<td>5</td>
<td>+1·98</td>
<td>t=0·74 P &gt; 0·6</td>
</tr>
</tbody>
</table>
In the asthmatic subjects, the dummy aerosols caused slightly greater bronchoconstriction than in the normal ones, but the effect was again prevented by prior inhalation of atropine (Table III).

**DISCUSSION**

There is some statistical evidence (Smith, 1966; Speizer et al., 1968a; Speizer et al., 1968b) to support the impression that the mortality rate from asthma has increased in this country in the last few years, particularly among younger patients. The reason for this increase is unknown, but it has coincided with the widespread use of pressurized sympathomimetic aerosols in the treatment of asthma, and these have therefore come under suspicion. Two possibilities are that overdosage with the active bronchodilator causes cardiac stimulation and eventually ventricular fibrillation (Greenberg and Pines, 1967) or that some asthmatics have a latent bronchoconstrictor response to isoprenaline (Keighley, 1966). A third possibility is that the propellant or surfactant used in the pressurized aerosols might have a bronchoconstrictor action, particularly when taken in larger than recommended doses, since it is known that non-specific irritants of the tracheobronchial tree can initiate reflex bronchoconstriction (Widdicombe, Kent, and Nadel, 1962).

In the present study the body plethysmograph was used to measure changes in airway resistance, since this is the most sensitive method of following changes in bronchoconstriction (Lloyd and Wright, 1963) and allows a correction to be made for the effect of lung volume on airway resistance, and on its reciprocal, airway conductance. A deliberate overdose of 10 puffs of the aerosol was used to ensure that subjects unfamiliar with the technique of inhalation obtained an adequate dose, and to bring out any small effects.

It was found that aerosols, consisting of an inert propellant and surfactant only, caused slight bronchoconstriction in normal subjects, and it is uncertain which constituent was responsible. Although the response was slightly larger when the surfactant was changed from sorbitol trioleate to lecithin, suggesting that the latter had a constrictor action, the increase was not statistically significant. It remains possible that part of the response was due to the dichlorodifluoroethane propellant. It should be stressed that, even with the lecithin aerosol, the response was too small to cause symptoms of wheezing, and the largest individual fall in SGaw was 25%, which is close to the average fall found after inhalation of a single cigarette (Nadel and Comroe, 1961; Sterling, 1967).

Since the inhalation of the aerosols frequently caused coughing, they probably stimulated the irritant receptors in the tracheobronchial tree, which form part of the afferent limb of a vagally mediated bronchomotor reflex (Widdicombe et al., 1962). The response was tested again after inhalation of atropine and was found to be abolished, which would support the hypothesis that it was due to a vagal reflex. The bronchoconstriction is probably analogous to that caused by inhalation of cigarette smoke, inert carbon particles or sulphur dioxide (Nadel, Salem, Tamplin, and Tokiwa, 1965).

The action of atropine is of interest in that the inhalation of only 0-2 mg. produced bronchodilatation which was similar in degree to that reported after the injection of 1-2 mg. (Widdicombe et al., 1962). This finding agrees with that of Altounyan (1964), who reported maximal increase in F.E.V.1 after inhalation of only 0-04 mg. of atropine methonitrate. Moreover, up to six times our dose (i.e., 1-2 mg.) could be inhaled without causing an increase in heart rate or symptomatic drying of the mouth, which suggests indirectly that it had little effect on bronchial secretions. The production of bronchodilatation shows that the atropine was more than adequate to counteract any bronchoconstrictor effect of its own propellant and surfactant, as well as preventing that due to subsequent inhalation of bronchial irritants. The weak bronchoconstrictor action of sorbitol trioleate was more than balanced in nine normal subjects by the addition of isoprenaline to the aerosol.

The response of the small group of asthmatics was essentially similar to that of the normal subjects, apart from a tendency to greater bronchoconstriction after inhalation of the aerosols. This agrees with previous suggestions that asthmatics show a more vigorous response to non-specific bronchoconstrictor stimuli than normal subjects (Altounyan, 1964).

It is impossible to exclude occasional idiosyncracy to the propellants as a factor in asthmatic mortality, but no such cases have been reported to date, and a large-scale survey would be needed to investigate this problem. What does emerge from the present study is the finding that, although the propellants used in two of the most popular aerosols have a bronchoconstrictor action, this is too feeble, even in a large dose, to cause any symptomatic wheezing, and is therefore most unlikely to be a clinical hazard even if the propel-
lants are combined with active agents other than bronchodilators. There is no evidence that other surfactants which we did not study, such as oleyl alcohol, are more irritant to the bronchi, and it is likely that the presence of a bronchodilator would be sufficient to overcome considerably greater bronchoconstrictor activity than that seen here. Although isoprenaline is very effective, atropine is a more specific antagonist of the propellant-induced bronchoconstriction because it blocks the effect of cholinergic neuromuscular transmission, and we have already suggested that the slight bronchoconstriction from inhaling aerosols is a vagally mediated reflex. It has the added advantage, when taken in a small dose by inhalation, of prolonging the action of isoprenaline (Chamberlain, Muir, and Kennedy, 1962) without causing any systemic effects or symptomatic drying up of secretions.

Our thanks are due to Miss F. A. Booher for her frequent technical help and to the subjects for their co-operation. The aerosols were kindly supplied by Riker Laboratories. During the course of this study G. M. S. was supported by a grant from the Board of Governors of St. George's Hospital, London, S.W.1.

REFERENCES
Kubler, H. (1964). Just how hazardous are propellants? The physiological properties of aerosol propellants. Aerosol Age, 9, April, p. 44.
Effect of aerosol propellants and surfactants on airway resistance
G. M. Sterling and J. C. Batten

Thorax 1969 24: 228-231
doi: 10.1136/thx.24.2.228

Updated information and services can be found at:
http://thorax.bmj.com/content/24/2/228

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/